GW Pharmaceuticals Shows Smaller Than Expected Q4 Loss
GW Pharmaceuticals reported its fiscal fourth-quarter financial results before the markets opened on Monday.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
GW Pharmaceuticals PLC (NASDAQ: GWPH) reported its fiscal fourth-quarter financial results before the markets opened on Monday. The company posted a net loss of $0.89 per share and $2.2 million in revenue. The consensus estimates from Thomson Reuters had called for a net loss of $1.58 per share and revenue of $3.6 million. In the same period of last year, it posted a $0.85 per share net loss and $8.46 million in revenue.
Operationally, Epidiolex (CBD) orphan epilepsy program in Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex and infantile spasms received positive results across its Phase 3 trials for these indications.
The program has also been expanded, with 98% of patients who complete Phase 3 trials have entered long-term extension. Over 1,000 patients are now on Epidiolex treatment. The withdrawal rate in long-term studies is approximately 20% as well.
[nativounit]
On the books, cash and cash equivalents totaled £374.4 million ($483.4 million) at the end of the quarter, compared to £234.9 million in the same period from last year.
Justin Gover, GW’s CEO, commented:
In 2016 GW has completed three positive Phase 3 trials for Epidiolex in patients with two different rare treatment resistant forms of childhood-onset epilepsy and we are making good progress towards an NDA submission. Our sights are now focused on Epidiolex approval and accelerating our preparations for a highly successful launch. Our goal is to provide the children and their families suffering from these highly treatment-resistant forms of childhood-onset epilepsy with a much needed new prescription option as quickly as possible.
Shares of GW Pharma traded up 2% early Monday to $114.59, with a consensus analyst price target of $146.00 and a 52-week trading range of $107.10 to $130.79.
[wallst_email_signup]
Contact [email protected] for any questions or corrections.
Chris Lange is a financial and geopolitical writer with more than a decade of experience covering a myriad of topics. He has published thousands of articles for 24/7 Wall St., with past coverage focused heavily on stocks, IPOs, healthcare, defense, global affairs, and technology.
His work has been quoted, or referenced by a number of outlets including Business Insider, USA Today, Yahoo Finance, MSN, The Motley Fool, and many other publications. A graduate of Southwestern University, he studied business with a focus on investments and has previous experience in banking and startups.
When not reading or writing the news, he is following his passion for Lacrosse, playing chess, or building solar projects with his dad.
